Saglam O - Search Results

1

Matricellular protein CCN1 (CYR61) expression is associated with high-grade ductal carcinoma in situ.

Saglam O, Dai F, Husain S, Zhan Y, Toruner G, Haines GK 3rd. Saglam O, et al. Hum Pathol. 2014 Jun;45(6):1269-75. doi: 10.1016/j.humpath.2014.02.007. Epub 2014 Feb 20. Hum Pathol. 2014. PMID: 24767859

2

AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.

Saglam O, Husain S, Toruner G. Saglam O, et al. Int J Gynecol Pathol. 2013 Sep;32(5):493-500. doi: 10.1097/PGP.0b013e31827fedef. Int J Gynecol Pathol. 2013. PMID: 23896716

3

Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.

Saglam O, Cao B, Wang X, Toruner GA, Conejo-Garcia JR. Saglam O, et al. PLoS One. 2022 Feb 28;17(2):e0264014. doi: 10.1371/journal.pone.0264014. eCollection 2022. PLoS One. 2022. PMID: 35226658 Free PMC article.

4

KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.

Saglam O, Tang Z, Tang G, Medeiros LJ, Toruner GA. Saglam O, et al. PLoS One. 2020 Sep 2;15(9):e0238477. doi: 10.1371/journal.pone.0238477. eCollection 2020. PLoS One. 2020. PMID: 32877461 Free PMC article.

5

ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.

Saglam O, Xiong Y, Marchion DC, Strosberg C, Wenham RM, Johnson JJ, Saeed-Vafa D, Cubitt C, Hakam A, Magliocco AM. Saglam O, et al. Cancer Control. 2017 Jan;24(1):89-95. doi: 10.1177/107327481702400115. Cancer Control. 2017. PMID: 28178720 Free PMC article.

6

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.

Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Mani NL, et al. Among authors: saglam o. Breast Cancer Res. 2016 Jul 29;18(1):78. doi: 10.1186/s13058-016-0737-x. Breast Cancer Res. 2016. PMID: 27473061 Free PMC article.

7

Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer.

Rutter CE, Yao X, Mancini BR, Aminawung JA, Chagpar AB, Saglam O, Hofstatter EW, Abu-Khalaf M, Gross CP, Evans SB. Rutter CE, et al. Among authors: saglam o. Clin Breast Cancer. 2016 Feb;16(1):59-62. doi: 10.1016/j.clbc.2015.09.008. Epub 2015 Sep 21. Clin Breast Cancer. 2016. PMID: 26483315

8

Stromal Overgrowth in a Brenner Tumor or Ovarian Fibroma With Minor Sex Cord Elements?

Ross JA, Saglam O. Ross JA, et al. Among authors: saglam o. Cancer Control. 2015 Jul;22(3):366-8. doi: 10.1177/107327481502200316. Cancer Control. 2015. PMID: 26351894 Free article.

9

PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.

Saglam O, Conejo-Garcia J. Saglam O, et al. Integr Cancer Sci Ther. 2018;5(2):10.15761/ICST.1000272. doi: 10.15761/ICST.1000272. Epub 2018 Apr 14. Integr Cancer Sci Ther. 2018. PMID: 29955379 Free PMC article.

10

Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.

Liegl-Atzwanger B, Heitzer E, Flicker K, Müller S, Ulz P, Saglam O, Tavassoli F, Devouassoux-Shisheboran M, Geigl J, Moinfar F. Liegl-Atzwanger B, et al. Among authors: saglam o. Mod Pathol. 2016 Oct;29(10):1262-77. doi: 10.1038/modpathol.2016.107. Epub 2016 Jul 1. Mod Pathol. 2016. PMID: 27363490 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters